Enfermedad
Lung cancer
CIE-10: C34 — Malignant neoplasm of bronchus and lung
Cifras clave
Solo valores publicados. Cada recuadro abre la sección que incluye su fuente, su año y su criterio.
- Intervalos de costos del tratamiento 5 intervalos publicados, cada uno con su fuente en la página de la fila
- Supervivencia a cinco años 28.7% 95% CI 28.6–28.9 · 2019–2021
- Hospitales con un registro publicado 8 para esta enfermedad, cada uno con su fuente publicada
- Ensayos clínicos 141 en reclutamiento o aún sin reclutar, según lo publicado
Detalles de la enfermedad
- Nombre en inglés
- Malignant neoplasm of bronchus and lung
También conocido como
- NSCLC
- SCLC
Intervalos de costos del tratamiento
Todos los intervalos de abajo se publican sobre una misma base de facturación: Antes del reembolso. Las fuentes no publican ninguna cifra posterior al reembolso, así que aquí no se muestra ninguna.
| Ruta de tratamiento | Intervalo de costos | Base del precio | Año de los datos |
|---|---|---|---|
| Cirugía | 52000 – 81790 CNY | Precio de paquete por enfermedad | 2020–2025 |
| Radioterapia | 19000 – 58000 CNY | Precio por ítem | 2025–2026 |
| Quimioterapia | 6550 – 9500 CNY | Precio de paquete por enfermedad | 2020–2021 |
| Terapia dirigida | 20000 – 60000 CNY | Precio por ítem | 2024–2025 |
| Inmunoterapia | 32043 – 43803 CNY | Precio por ítem | 2024–2025 |
Las barras comparten una sola escala en todas las filas de arriba: cada una empieza en la cifra publicada más baja de su fila y termina en la más alta. La cifra superior más alta de esta página es 81790 CNY. Cada fila conserva su propio año de datos y su criterio.
5 intervalos de costos para esta enfermedad, cada uno con su fuente en la página de la fila.
Los valores escritos en chino se citan tal como los publica la fuente.
Supervivencia a cinco años
Tasa de supervivencia a 5 años 28.7% IC del 95% 28.6–28.9
- Población
- Global (todos los estadios combinados) · Supervivencia relativa estandarizada por edad
- Período
- 2019–2021
- Publicador
- Centro Nacional del Cáncer de China
- Naturaleza del valor
- Valor estimado (análisis híbrido)
- Alcance del registro
- 281 registros de cáncer de base poblacional
- Disponibilidad de datos por estadio
- No publicado por estadio (la fuente solo publica la cifra global)
Los valores escritos en chino se citan tal como los publica la fuente.
Cómo leer esta cifra. Se publica para todos los estadios combinados, así que es un promedio de todas las personas de los datos del registro nacional y no un pronóstico para una persona. En la mayoría de los cánceres, el estadio en el momento del diagnóstico es el factor único más determinante de las diferencias de supervivencia: la supervivencia suele ser mayor cuando el cáncer se detecta en un estadio más temprano y menor cuando se detecta más tarde. Las comparaciones entre cánceres también dependen de con qué antelación o retraso suele diagnosticarse cada uno, así que una cifra más baja no significa por sí sola peor atención.
La cifra es de supervivencia relativa: compara a las personas diagnosticadas de este cáncer con personas de la misma edad y sexo de la población general, y está estandarizada por edad, así que no es la proporción de pacientes que siguen vivos a los cinco años. Se publica como un valor estimado (análisis híbrido) porque los informes de los registros llegan con retraso, así que el Centro Nacional del Cáncer modeló el período más reciente. Como contexto, la misma fuente publica una supervivencia relativa a cinco años del 43,7% para todos los cánceres combinados en 2019–2021.
Hospitales con un registro publicado para esta enfermedad
Seleccionados con fuentes de datos públicas oficiales
Estos hospitales se seleccionan de fuentes de datos públicas oficiales —los rankings de reputación por especialidad de hospitales de la Universidad de Fudan, la lista de especialidades clínicas clave nacionales y los centros nacionales de investigación clínica—, de modo que cada línea de una tarjeta se puede contrastar con su fuente publicada. No es un listado pagado ni promocionado.
Cómo se seleccionaron estos hospitales
Inclusión. Un hospital se lista para una enfermedad cuando la especialidad en la que esta se clasifica cumple al menos una de estas condiciones: un puesto o una nominación en el ranking de reputación por especialidad de hospitales de la Universidad de Fudan; un registro de especialidad clínica clave nacional de nivel A, B o C; o un centro nacional de investigación clínica o un laboratorio estatal clave en esa especialidad. La acreditación JCI se muestra como distintivo; nunca decide la inclusión ni el orden.
Orden. Paso 1: un puesto de Fudan entre 1 y 10 en la especialidad. Paso 2: otro puesto de Fudan, o una nominación. Paso 3: una especialidad clínica clave nacional de nivel A. Paso 4: una especialidad clínica clave nacional de nivel B. Paso 5: un centro nacional de investigación clínica o un laboratorio estatal clave en la especialidad, primero el centro y luego el laboratorio. Paso 6: una especialidad clínica clave nacional de nivel C, que es un registro que publicamos sin una fuente oficial independiente y que por eso se lista después de los demás.
Empates. Dentro de un mismo paso: primero el puesto de Fudan más alto, luego el nivel de especialidad clave más fuerte (A antes que B antes que C), luego la provincia, luego la ciudad y luego el nombre del hospital, el mismo orden provincia-ciudad-nombre que usa el directorio de hospitales. Se listan como máximo ocho hospitales.
Cuando la lista es corta. Cinco hospitales o más: se listan los ocho primeros. Tres o cuatro: se listan todos y un pliegue adicional añade los registros restantes hasta ocho, cada uno con su nivel de evidencia. Uno o dos: lo mismo, con ese pliegue abierto y una línea que indica cuántos hospitales tienen un historial público sólido. Ninguno: la página declara que no se encontró ningún historial público sólido y enlaza al directorio de especialidades. Nunca se inventa un puesto, una institución ni un recuento para rellenar la lista.
Los rankings de Fudan son el ranking de reputación por especialidad de hospitales más ampliamente reconocido por los clínicos chinos, publicado cada año por el instituto de gestión hospitalaria de la Universidad de Fudan.
-
First Affiliated Hospital of Guangzhou Medical University
Ranking de reputación por especialidad de Fudan 2023
- Cirugía torácica #5 https://www.fdygs.com/news2023-1.aspx
- Neumología #1 https://www.fdygs.com/news2023-1.aspx
Especialidad clínica clave nacional
- Neumología (nivel B) https://www.gyfyyy.cn/cn/news/xwsd/index_88.html
- Cirugía torácica (nivel B) https://www.gyfyyy.cn/cn/news/xwsd/index_88.html
Plataforma de investigación
- Centro Nacional de Investigación Clínica en Enfermedades Respiratorias https://www.most.gov.cn/tztg/201306/t20130608_106459.html
Investigación publicada
- From phenotypic associations to clinical triage: promise and pitfalls of fusion-prediction models in non-small cell lung cancer. Journal of thoracic disease, 2026
- Development of clinical-radiological prediction models to prioritize ALK, ROS1, and RET fusion testing in major driver alteration-negative non-small cell lung cancer. Journal of thoracic disease, 2026
4 estudios publicados más
PubMed indexa 6 artículos sobre esta enfermedad que mencionan este hospital.
También en el ranking: Urología nominado en la lista de Fudan.
-
Cancer Hospital of Chinese Academy of Medical Sciences
Ranking de reputación por especialidad de Fudan 2023
- Cirugía torácica #1 https://www.fdygs.com/news2023-1.aspx
Especialidad clínica clave nacional
- Cirugía torácica (nivel B) https://www.cicams.ac.cn/news/401.html
Investigación publicada
- A plain language summary of results from the CHOICE-01 trial of toripalimab plus chemotherapy for advanced non-small cell lung cancer (NSCLC). Future oncology (London, England), 2025
- Toripalimab plus chemotherapy for first line treatment of advanced non-small cell lung cancer (CHOICE-01): final OS and biomarker exploration of a randomized, double-blind, phase 3 trial. Signal transduction and targeted therapy, 2024
3 estudios publicados más
PubMed indexa 5 artículos sobre esta enfermedad que mencionan este hospital.
También en el ranking: Oncología médica #1, Urología nominado en la lista de Fudan.
-
Shanghai Chest Hospital
Ranking de reputación por especialidad de Fudan 2023
- Cirugía torácica #2 https://www.fdygs.com/news2023-1.aspx
Especialidad clínica clave nacional
- Cirugía torácica (nivel B) https://www.shxkyy.com/hz/list/190/1400.html
Investigación publicada
- Best practices for respiratory function training in perioperative patients with lung cancer: A scoping review and evidence synthesis. Asia-Pacific journal of oncology nursing, 2026
- Patient-reported outcomes with a personalized follow-up program after lung cancer resection: A single-center randomized controlled trial. Asia-Pacific journal of oncology nursing, 2026
3 estudios publicados más
PubMed indexa 5 artículos sobre esta enfermedad que mencionan este hospital.
-
China-Japan Friendship Hospital
Ranking de reputación por especialidad de Fudan 2023
- Neumología #2 https://www.fdygs.com/news2023-1.aspx
- Cirugía torácica nominado https://www.fdygs.com/news2023-1.aspx
Especialidad clínica clave nacional
- Neumología (nivel B) https://www.zryhyy.com.cn/zryh/c100020/202309/47e8245aa93343baac89762d4e80580f.shtml
- Cirugía torácica (nivel B) https://www.zryhyy.com.cn/zryh/c100020/202309/47e8245aa93343baac89762d4e80580f.shtml
Investigación publicada
- Development and validation of an interpretable model for pre-chemotherapy triage of fatigue-pain-sleep disturbance burden in lung cancer. European journal of oncology nursing : the official journal of European Oncology Nursing Society, 2026
- CLIC4 inhibits the progression of non-small cell lung cancer by suppressing the MAPK pathway. Scientific reports, 2026
2 estudios publicados más
PubMed indexa 4 artículos sobre esta enfermedad que mencionan este hospital.
-
West China Hospital, Sichuan University
Ranking de reputación por especialidad de Fudan 2023
- Cirugía torácica #4 https://www.fdygs.com/news2023-1.aspx
- Neumología #3 https://www.fdygs.com/news2023-1.aspx
Especialidad clínica clave nacional
- Neumología (nivel A) https://wcums.scu.edu.cn/kxyan_jiu/gjlczdzk.htm
- Cirugía torácica (nivel A) https://wcums.scu.edu.cn/kxyan_jiu/gjlczdzk.htm
También en el ranking: Cirugía general #3, Urología #2 (empatado), Otorrinolaringología #8 en la lista de Fudan.
-
Shanghai Pulmonary Hospital
Ranking de reputación por especialidad de Fudan 2023
- Cirugía torácica #3 https://www.fdygs.com/news2023-1.aspx
- Neumología nominado https://www.fdygs.com/news2023-1.aspx
Especialidad clínica clave nacional
Investigación publicada
- Integrating proteomics and metabolomics to reveal MAT2A for metabolic reprogramming in non-small cell lung cancer cells. iScience, 2026
- SYS6010, epidermal growth factor receptor-targeting antibody-drug conjugate for advanced non-small cell lung cancer: A phase 1 trial. Cancer cell, 2026
11 estudios publicados más
PubMed indexa 13 artículos sobre esta enfermedad que mencionan este hospital.
-
Peking Union Medical College Hospital
Ranking de reputación por especialidad de Fudan 2023
- Neumología #4 https://www.fdygs.com/news2023-1.aspx
- Cirugía torácica nominado https://www.fdygs.com/news2023-1.aspx
También en el ranking: Cirugía general #1, Urología #8, Ginecología #1 en la lista de Fudan.
-
Ruijin Hospital
Ranking de reputación por especialidad de Fudan 2023
- Cirugía torácica #7 (empatado) https://www.fdygs.com/news2023-1.aspx
- Neumología #5 https://www.fdygs.com/news2023-1.aspx
Especialidad clínica clave nacional
- Neumología (nivel B) https://www.rjh.com.cn/2018RJPortal/lcyxy2019/sy/jj/index.shtml
Investigación publicada
- Recent Advances and Future Challenges of Bispecific Antibodies in Lung Cancer. Critical reviews in oncology/hematology, 2026
- Attenuated Salmonella typhimurium VNP20009 L-forms suppress tumor growth and metastasis by inhibiting TGF-β1/Snail/Vimentin pathway in murine lung cancer. European journal of pharmacology, 2026
PubMed indexa 2 artículos sobre esta enfermedad que mencionan este hospital.
También en el ranking: Cirugía general #4, Enfermedades infecciosas #6, Medicina nuclear #10 en la lista de Fudan.
Ensayos clínicos (tratamientos en investigación)
Además de la atención estándar, es posible que actualmente haya estudios de investigación clínica para Lung cancer abiertos a participantes en China. Los tratamientos en estudio no han sido aprobados por el regulador como terapia estándar: son investigación clínica, no tratamiento de rutina. Cada registro indica el investigador principal y el hospital que realiza el estudio. Si te interesa, contacta con el hospital para preguntar por los criterios de elegibilidad y decide si solicitas participar.
-
Estudio A Randomized, Double-Blind, Placebo-Controlled, Multi-Regional Phase III Clinical Study of Toripalimab Alone or in Combination With Tifcemalimab (JS004/TAB004) as Consolidation Therapy in Patients With Limited-Stage Small Cell Lung Cancer Without Disease Progression Following Chemoradiotherapy
- Hospital
- Third Affiliated Hospital of Harbin Medical University
- Estado
- En reclutamiento
- Registro
- NCT06095583
-
Estudio A Phase 1/2 Adaptive Dose-Escalation and Expansion Study of Dual-Targeting Chimeric Antigen Receptor Natural Killer (CAR-NK) Cells Directed Against DLL3, CD56 (NCAM1), and/or GD2 in Adults With Relapsed/Refractory Small Cell Lung Cancer
- Hospital
- Peking University Shenzhen Hospital
- Estado
- En reclutamiento
- Registro
- NCT07480213
-
Estudio A Multicenter, Open-label, Randomized, Prospective Clinical Study of Adebrelimab Consolidation Therapy for Limited-Stage Small-Cell Lung Cancer (LS-SCLC) Without Progression After Concurrent Chemoradiotherapy
- Investigador principal
- Qiming Wang · Director
- Hospital
- Henan Cancer Hospital
- Estado
- En reclutamiento
- Registro
- NCT07559786
-
Estudio Efficacy and Safety of Prophylactic Cranial Irradiation Versus MRI Surveillance in Patients With Limited-stage Small Cell Lung Cancer Who Achieved Remission After First-line Chemoradiotherapy: a Multicenter Randomized Controlled Phase III Clinical Trial
- Investigador principal
- Jinming Yu · Director of Shandong Cancer Hospital and Institute
- Hospital
- Shandong Cancer Hospital
- Estado
- En reclutamiento
- Registro
- NCT04829708
-
Estudio Small Extracellular Vesicle miRNAs as Predictive Biomarkers for Immunochemotherapy Efficacy in Extensive-stage Small Cell Lung Cancer
- Investigador principal
- Wei Zhang · Chief Physician
- Hospital
- Shanghai Chest Hospital
- Estado
- En reclutamiento
- Registro
- NCT07070011
136 estudios registrados más
-
Estudio A Phase II, Single-Arm, Prospective Study of Neoadjuvant Icotinib With Chemotherapy for the Treatment of Patients With Epidermal Growth Factor Receptor Mutation Positive, Resectable for Stage II to IIIB(N2) Non-small Cell Lung Cancer
- Investigador principal
- Wu Nan · Principal Investigator
- Hospital
- Peking University Cancer Hospital
- Estado
- En reclutamiento
- Registro
- NCT05104788
-
Estudio A Phase I Study to Evaluate the Safety and Preliminary Efficacy of [225Ac]Ac-DOTATATE Injection Combined With Tislelizumab in the Maintenance Treatment Period for Patients of Extensive-stage Small Cell Lung Cancer (ES-SCLC) With Somatostatin Receptors (SSTR)+ as First-line Treatment
- Hospital
- Peking University Cancer Hospital
- Estado
- En reclutamiento
- Registro
- NCT07413042
-
Estudio Neoadjuvant Sintilimab or Combined With Chemotherapy for Stage III Driven Gene Mutation Negative Non-small Cell Lung Cancer
- Investigador principal
- Peng Zhang · Director of thoracic department
- Hospital
- Shanghai Pulmonary Hospital
- Estado
- En reclutamiento
- Registro
- NCT04728724
-
Estudio Disitamab Vedotin in Combination with Tislelizumab and Bevacizumab in a Phase II Clinical Study of Locally Advanced or Metastatic Non-small Cell Lung Cancer with HER2 Mutation/amplification/expression
- Investigador principal
- Chunxia Su · Director of the Clinical Research Center
- Hospital
- Shanghai Pulmonary Hospital
- Estado
- En reclutamiento
- Registro
- NCT06749860
-
Estudio Evaluation of AI-Assisted Versus Conventional Human Reading for Lung Cancer Screening in Community-Based Settings: A Randomized Controlled Trial
- Investigador principal
- Jianxing He · Professor
- Hospital
- First Affiliated Hospital of Guangzhou Medical University
- Estado
- En reclutamiento
- Registro
- NCT06988579
-
Estudio Construction and Evaluation of a Hospital-Community Health Collaboration Model Empowered by Digital Technology for Lung Cancer Screening
- Investigador principal
- Jianxing He · Director
- Hospital
- First Affiliated Hospital of Guangzhou Medical University
- Estado
- En reclutamiento
- Registro
- NCT06988943
-
Estudio Establishing a Longitudinal Cohort Study of Lung Cancer Using Tissue and Peripheral Blood Metabolomics to Explore Biomarkers and Therapeutic Mechanisms.
- Investigador principal
- Jianxing He · Professor
- Hospital
- First Affiliated Hospital of Guangzhou Medical University
- Estado
- En reclutamiento
- Registro
- NCT06843707
-
Estudio Efficiency and Safety of Microwave Ablation Plus Immune Checkpoint Inhibitor for Patients With Multiple Primary Lung Cancer: A Open, Multi-center, Phase II Clinical Trial
- Investigador principal
- Chang Chen
- Estado
- En reclutamiento
- Registro
- NCT05053802
-
Estudio A Phase 1/2 Study Evaluating the Safety and Efficacy of Amivantamab and Olomorasib Combination Therapy in Metastatic Non-small Cell Lung Cancer
- Hospital
- The First Affiliated Hospital, Sun Yat-sen University
- Estado
- En reclutamiento
- Registro
- NCT07227025
-
Estudio A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Anti-Tumor Efficacy and Safety of Sunvozertinib Versus Placebo as Adjuvant Therapy in Patients With Stage IB-IIIA Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations or PACC Mutations After Radical Surgery (WU-KONG16)
- Hospital
- Peking University Cancer Hospital
- Estado
- En reclutamiento
- Registro
- NCT07182682
-
Estudio Phase II Study of Neoadjuvant CT-Guided Intra-tumor Double Checkpoint Blockades for Untreated Stage I-IIIA Non-Small Cell Lung Cancers Amenable for Surgical Resection
- Hospital
- The Second Affiliated Hospital of Guangzhou Medical University
- Estado
- En reclutamiento
- Registro
- NCT06492421
-
Estudio A Phase III, Multicenter, Randomized, Controlled, Open-label Clinical Study to Evaluate the Efficacy and Safety of YL201 in Combination With Serplulimab Versus Carboplatin and Etoposide in Combination With Serplulimab as First-line Treatment in Participants With Treatment-naïve Extensive-stage Small Cell Lung Cancer
- Hospital
- Sun Yat-sen University Cancer Center
- Estado
- En reclutamiento
- Registro
- NCT07739758
-
Estudio Efficacy and Safety of Cryo-Thermal Ablation Combined With Toripalimab and Chemotherapy as Neoadjuvant Treatment for Resectable Stage IB-IIIB Non-Small Cell Lung Cancer: A Multicenter, Single-Arm, Prospective Phase II Clinical Trial
- Investigador principal
- Hu Liao · Deputy Director & Medical Team Leader, Department of Thoracic Surgery, West China Hospital, Sichuan University; Associate Professor of Surgery; Master's Supervisor
- Hospital
- The Third People's Hospital of Chengdu
- Estado
- En reclutamiento
- Registro
- NCT07855965
-
Estudio A Phase 1/2 Adaptive Dose-Escalation and Expansion Study of Dual-Targeting Chimeric Antigen Receptor Natural Killer (CAR-NK) Cells Directed Against DLL3, CD56 (NCAM1), and/or GD2 in Adults With Relapsed/Refractory Small Cell Lung Cancer
- Hospital
- Peking University Shenzhen Hospital
- Estado
- En reclutamiento
- Registro
- NCT07744256
-
Estudio A Phase III, Randomized, Open-Label Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Patients With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
- Hospital
- First Affiliated Hospital of Guangzhou Medical University
- Estado
- En reclutamiento
- Registro
- NCT06793215
-
Estudio A Prospective, Single Arm, Phase II Clinical Study of Tislelizumab Combined With Chemotherapy Followed by Thoracic Consolidation Radiotherapy in the First-line Treatment of Extensive Stage Small Cell Lung Cancer
- Investigador principal
- Wei Zhou · Department Director
- Hospital
- Chongqing University Cancer Hospital
- Estado
- En reclutamiento
- Registro
- NCT07425795
-
Estudio Immunonutrition in Reducing Acute Esophagitis After Thoracic Radiotherapy in Lung Cancer: a Prospective, Randomized, Controlled, Open-label Clinical Trial
- Investigador principal
- HuaiLiu · Prof.
- Hospital
- Hunan Cancer Hospital
- Estado
- En reclutamiento
- Registro
- NCT06840704
-
Estudio A Phase Ib/III Clinical Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Immunogenicity of HS-20117 Combined With Aumolertinib in Participants With Advanced Non-Squamous Non-Small Cell Lung Cancer
- Hospital
- Tianjin Medical University Cancer Institute & Hospital
- Estado
- En reclutamiento
- Registro
- NCT06417008
-
Estudio A Multicenter, Open-label, Dose-Escalation and Dose-Expansion Phase I/II Study of ZG005 Combined With Gecacitinib in Patients With Advanced Non-Small Cell Lung Cancer
- Hospital
- Shanghai Chest Hospital
- Estado
- En reclutamiento
- Registro
- NCT06903377
-
Estudio A Study of QL1706 Combined With Chemotherapy Induction on Sequential Immunotherapy Consolidation in Patients With Limited-Stage Small Cell Lung Cancer After Chemoradiotherapy：A Phase II Trial
- Investigador principal
- Xuwei Cai · Director
- Hospital
- Shanghai Chest Hospital
- Estado
- En reclutamiento
- Registro
- NCT07091305
-
Estudio A Multicenter, Randomized, Controlled, Open-label, Phase IIa Trial on Autologous Tumor Infiltrating Lymphocyte Injection (LM103 TILs) for the Adjuvant Treatment of Non-small Cell Lung Cancer With Negative Driver Gene Mutations
- Hospital
- Guangdong Provincial People's Hospital
- Estado
- En reclutamiento
- Registro
- NCT07444437
-
Estudio Neoadjuvant Therapy With Toripalimab and JS004 Combined With Etoposide and Platinum Chemotherapy for Limited-stage Small Cell Lung Cancer : A Single-arm, Phase 2 Trial
- Investigador principal
- Peng Zhang · Director
- Hospital
- Shanghai Pulmonary Hospital
- Estado
- En reclutamiento
- Registro
- NCT06256237
-
Estudio Exploration on the Value of Molecular Residual Disease Based on Circulating Tumor DNA Detection in Predicting Recurrence of Resected Non-small Cell Lung Cancer
- Investigador principal
- Peng Zhang · Professor
- Hospital
- Shanghai Pulmonary Hospital
- Estado
- En reclutamiento
- Registro
- NCT05965024
-
Estudio Patient-derived Tumor-like Cell Cluster Model-based Precision Treatment Strategy on Non-small Cell Lung Cancer: a Prospective, Observational Study
- Investigador principal
- Chang Chen · Deputy Director of MD. PhD. Program in Thoracic Surgery, Secretary of the party committee of Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, China
- Hospital
- Shanghai Pulmonary Hospital
- Estado
- En reclutamiento
- Registro
- NCT07328945
-
Estudio Safety, Tolerability, Pharmacokinetics, Immunogenicity and Preliminary Efficacy Study of the Combination Therapy With HC010 for Injection in Patients With Advanced Solid Tumors:A Multicenter, Open-Label, Dose Range-Finding and Multiple Cohort Dose Expansion Phase Ib Clinical Trial-Lung Cancer Population
- Hospital
- Sun Yat-sen University Cancer Center
- Estado
- En reclutamiento
- Registro
- NCT07381829
-
Estudio A Prospective, Single-arm, Multicenter, Phase II Clinical Study on Envafolimab Combined With Disitamab Vedotin And Carboplatin for Resectable, Stage II-III, HER2-Mutant Non-Small Cell Lung Cancer
- Hospital
- Guangdong Provincial People's Hospital
- Estado
- En reclutamiento
- Registro
- NCT06734182
-
Estudio A Multicenter Phase II/III Study Evaluating the Efficacy and Safety of SCTB41 Combined With Chemotherapy Versus Tislelizumab Combined With Chemotherapy as First-Line Treatment for Driver-Negative Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
- Hospital
- Guangdong Provincial People's Hospital
- Estado
- En reclutamiento
- Registro
- NCT07662395
-
Estudio A Randomized, Open Label, Multicenter, Phase 3 Trial Evaluating the Efficacy and Safety of TAK-928 Versus Docetaxel in Participants With Unresectable Locally Advanced or Metastatic Non-Small Cell Lung Cancer With Disease Progression on or After Platinum-Based Chemotherapy and Anti-PD-1/PD-L1 Immunotherapy
- Hospital
- The First Affiliated Hospital of Anhui Medical University
- Estado
- En reclutamiento
- Registro
- NCT07217301
-
Estudio An Open-label, Multicenter Study of ZL-1310 to Evaluate the Safety, Efficacy, and Pharmacokinetics in Participants With Small Cell Lung Cancer
- Hospital
- The First Affiliated Hospital of Anhui Medical University
- Estado
- En reclutamiento
- Registro
- NCT06179069
-
Estudio Comparison of Segmentectomy Versus Lobectomy for Early-stage Non-small Cell Lung Cancer ≤ 2 cm in the Middle Third of the Lung Field: A Prospective and Multi-center RCT Study
- Hospital
- Jiangsu Province Hospital
- Estado
- En reclutamiento
- Registro
- NCT04944563
-
Estudio PADL1NK-005: A Randomized, Phase 3, Open-Label Study to Evaluate PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
- Hospital
- Anhui Provincial Hospital
- Estado
- En reclutamiento
- Registro
- NCT07144280
-
Estudio DAREON ® -Lung-1: A Phase III Multi-center, Open-label, Randomised Trial of Intravenous Obrixtamig in Combination With Atezolizumab, Carboplatin, and Etoposide vs. Atezolizumab, Carboplatin, and Etoposide as First-line Treatment in Patients With Extensive-stage Small Cell Lung Cancer
- Hospital
- Peking University Cancer Hospital
- Estado
- En reclutamiento
- Registro
- NCT07472517
-
Estudio A Global, Multicenter, Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan Versus Standard of Care (SOC) in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer (ES-SCLC)
- Hospital
- Peking University Cancer Hospital
- Estado
- En reclutamiento
- Registro
- NCT06801834
-
Estudio A Phase 3, Multicenter, Randomized, Open-label Study Evaluating Efficacy of Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Subjects With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers, Negative for PD-L1, and Positive for KRAS p.G12C (CodeBreaK 202)
- Hospital
- First Affiliated Hospital of Guangzhou Medical University
- Estado
- En reclutamiento
- Registro
- NCT05920356
-
Estudio Tranexamic Acid Use for Bleeding Prevention in the Surgical Treatment of Metastatic Spinal Tumor in Lung Cancer Patients: a Triple Blinded, Randomized Controlled Trial to Assess the Efficacy of Tranexamic Acid for Hemostasis
- Hospital
- The Second Affiliated Hospital Zhejiang University School of Medicine
- Estado
- En reclutamiento
- Registro
- NCT06023212
-
Estudio A Phase I/II Multicenter, Open Label, Single-arm Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of WSD0922-FU in the Treatment of Advanced Non-small Cell Lung Cancer
- Hospital
- Anhui Provincial Hospital
- Estado
- En reclutamiento
- Registro
- NCT06631989
-
Estudio Targeting Delta-like Ligand 3 (DLL3) With 68Ga-PFD3 PET/CT for the Diagnosis and Assessment of Small Cell Lung Cancer (SCLC)
- Investigador principal
- Tingting Yuan · Attending physician
- Hospital
- Peking University First Hospital
- Estado
- En reclutamiento
- Registro
- NCT07508852
-
Estudio Effectiveness of Acupuncture Combined With PD-1/PD-L1 Inhibitors for Advanced Lung Cancer：A Randomized Controlled Clinical Study
- Investigador principal
- Liu Zhishun · professer，Chief Physician
- Hospital
- The First Affiliated Hospital of Anhui Medical University
- Estado
- En reclutamiento
- Registro
- NCT06926140
-
Estudio TCR-T Cells Targeting Cancer Cells for Immunotherapy of Lung Cancer and Other Solid Tumors: Phase I Clinical Trial
- Hospital
- The Second Affiliated Hospital of Guangzhou Medical University
- Estado
- En reclutamiento
- Registro
- NCT03778814
-
Estudio Observational Study on the Efficacy and Safety of Huaier Granules Compared With Platinum Containing Dual Drug Combination Chemotherapy in Adjuvant Therapy for Resectable Stage II-IIIA Non-small Cell Lung Cancer After Radical Surgery
- Investigador principal
- Hongxu Liu · professor
- Hospital
- Liaoning Cancer Hospital
- Estado
- En reclutamiento
- Registro
- NCT06109454
-
Estudio Prospective, Single-arm Phase II Clinical Study of Single-drug Chemotherapy Plus Immunotherapy in Metastatic Non-small Cell Lung Cancer Elderly Patients
- Investigador principal
- HAN GUANG · Chief physician
- Hospital
- Hubei Cancer Hospital
- Estado
- En reclutamiento
- Registro
- NCT06032052
-
Estudio ROSETTA Lung-201: A Randomized, Multicenter, Open-label Phase 3 Study of Pumitamig Monotherapy Compared to Durvalumab in Participants With Unresectable Stage III NSCLC Without Progression After Platinum-based Concurrent Chemoradiation Therapy.
- Hospital
- Peking University Cancer Hospital
- Estado
- En reclutamiento
- Registro
- NCT07361497
-
Estudio A Single Arm, Open Label, Dose-escalating, Prospective Phase I Clinical Trial Evaluating the Safety, Tolerability and Efficacy of TMT101 Injection Alone in Patients With Advanced Pancreatic Cancer or Non-small Cell Lung Cancer(NSCLC) After Standard Treatment Failure
- Investigador principal
- Wu Wenming · Director, Chief Physician of Basic Surgery, Principal Investigator, Clinical Professor
- Hospital
- Peking Union Medical College Hospital
- Estado
- En reclutamiento
- Registro
- NCT06861543
-
Estudio A Prospective Cohort Study of Zorifertinib as a First-line Treatment in Patients With Epidermal Growth Factor Receptor-mutant Advanced Non-small Cell Lung Cancer With Central Nervous System (CNS) Metastases
- Hospital
- The First Affiliated Hospital of Anhui Medical University
- Estado
- En reclutamiento
- Registro
- NCT07143045
-
Estudio Low-dose Radiation Therapy and Stereotactic Body Radiation Therapy Combined With PD-1 Inhibitor Sintilimab and Chemotherapy Versus PD-1 Inhibitor Combined With Chemotherapy as First-line Treatment for Patients With Locally Advanced or Metastatic Squamous Cell Lung Cancer: A Randomized, Phase II Multicenter Clinical Trial
- Investigador principal
- You Lu · Chair of Division of Thoracic Tumor Multimodality Treatment
- Hospital
- The Second Affiliated Hospital of Chongqing Medical University
- Estado
- En reclutamiento
- Registro
- NCT06121505
-
Estudio Delta-like Protein 3 (DLL3)- Targeted PET Imaging in Small Cell Lung Cancer
- Hospital
- First Affiliated Hospital of Guangzhou Medical University
- Estado
- En reclutamiento
- Registro
- NCT07677787
-
Estudio Randomized, Double-Blind, Multicenter Phase III Study of RC148 in Combination With Platinum-Based Chemotherapy Versus Tislelizumab in Combination With Platinum-Based Chemotherapy as First-Line Treatment for Advanced Squamous Non-Small Cell Lung Cancer
- Hospital
- The First Affiliated Hospital of Anhui Medical University
- Estado
- En reclutamiento
- Registro
- NCT07416474
-
Estudio A Phase III, Randomised, Double-blind, Placebo-controlled, Multi-centre Study of Almonertinib as Maintenance Therapy in Patients With Locally Advanced, Unresectable EGFR Mutation-positive Non-Small Cell Lung Cancer (Stage III) Who Have Not Progressed Following Definitive, Platinum-based Chemoradiation Therapy
- Hospital
- Shandong Cancer Hospital
- Estado
- En reclutamiento
- Registro
- NCT04951635
-
Estudio The Therapeutic Effect of Irinotecan Liposomes Combined With Cisplatin/Carboplatin for Platinum Sensitive Recurrent Small Cell Lung Cancer
- Estado
- En reclutamiento
- Registro
- NCT06467786
-
Estudio A Phase II Clinical Study to Evaluate the Efficacy and Safety of SKB571 Combination Therapy in Participants With Non-Small Cell Lung Cancer (NSCLC)
- Hospital
- Peking University Cancer Hospital
- Estado
- En reclutamiento
- Registro
- NCT07622186
-
Estudio Efficacy and Safety of PD-L1 Inhibitor Rechallenge After Immune Checkpoint Inhibitor-Related Pneumonitis in Patients With Lung Cancer: A Multicenter Real-World Study
- Hospital
- First Affiliated Hospital of Guangzhou Medical University
- Estado
- En reclutamiento
- Registro
- NCT07775820
-
Estudio Tubeless Anesthesia in Preventing Contralateral Lung Complications in Patients Undergoing Single-Port Thoracoscopic Surgery for Early-Stage Lung Cancer: A Single-Center, Prospective, Open-Label, Randomized Controlled Trial
- Hospital
- Fujian Medical University Union Hospital
- Estado
- En reclutamiento
- Registro
- NCT07024433
-
Estudio Effectiveness of Perioperative Percutaneous Acupoint Acupuncture on Postoperative Sleep Disturbances in Patients Undergoing Video-Assisted Thoracoscopic Lung Cancer Resection: A Prospective, Randomized, Single-Blind, Superiority Controlled Trial
- Investigador principal
- LIna Huang · Chief Physician, Department of Anesthesiology, Shanghai First People's Hospital
- Hospital
- Shanghai General Hospital
- Estado
- En reclutamiento
- Registro
- NCT07662733
-
Estudio Electroacupuncture Combined With 5-HT3 Receptor Inhibitor for the Prevention of Postoperative Nausea and Vomiting in High-risk Patients Undergoing Thoracoscopic Surgery for Lung Cancer
- Investigador principal
- Cai Xiaoyue · Associate Chief Physician
- Hospital
- Shanghai Chest Hospital
- Estado
- En reclutamiento
- Registro
- NCT07515027
-
Estudio Molecular Landscape of Primary and Acquired Resistance to Immune Checkpoint Inhibitors in Patients With Chinese Advanced Non-small Cell Lung Cancer
- Investigador principal
- Xiaomin Niu · Principal Investigator
- Hospital
- Shanghai Chest Hospital
- Estado
- En reclutamiento
- Registro
- NCT04977791
-
Estudio Randomized Controlled Study on Improving Patient-reported Outcomes After Lung Cancer Surgery With Mobile Internet Platform
- Investigador principal
- Xinghua Cheng · Director, Head of Oncology Surgery, Clinical Professor
- Hospital
- Shanghai Chest Hospital
- Estado
- En reclutamiento
- Registro
- NCT06483295
-
Estudio The Efficacy and Safety of the Combination of Sintilimab With Platinum-doublet Chemotherapy and Adaptive Radiotherapy Strategy in the Treatment of Stage III Non-small Cell Lung Cancer Patients
- Investigador principal
- Xuewen Liu · Professor
- Hospital
- Hunan Cancer Hospital
- Estado
- En reclutamiento
- Registro
- NCT07138755
-
Estudio A Phase I Clinical Study to Explore the Safety and Efficacy of Hypervision Proton Surgery (HyPROS) for Early-stage Non-small Cell Lung Cancer
- Investigador principal
- Shuanghu Yuan · Professor
- Hospital
- Anhui Provincial Hospital
- Estado
- En reclutamiento
- Registro
- NCT07195084
-
Estudio A Multicenter, Randomized, Double-blind, Phase III Clinical Study of Comparing the Efficacy and Safety of AK112 (PD-1/VEGF Bispecific Antibody) Versus Placebo as Consolidation Treatment for Patients With Limited Stage Small-Cell Lung Cancer Who Have Not Progressed Following Concurrent Chemoradiation Therapy
- Hospital
- Peking University Cancer Hospital
- Estado
- En reclutamiento
- Registro
- NCT07010263
-
Estudio Prospective Cohort Study on Risk Factors and Machine Learning-Based Prediction of Postoperative Venous Thromboembolism in Patients Undergoing Lung Cancer Surgery
- Hospital
- The First Hospital of Jilin University
- Estado
- En reclutamiento
- Registro
- NCT07439991
-
Estudio An Open Label, First-in-human Study of BAY 2927088 in Participants With Advanced Non-small Cell Lung Cancer (NSCLC) Harboring an EGFR and/or HER2 Mutation
- Hospital
- Peking University Cancer Hospital
- Estado
- En reclutamiento
- Registro
- NCT05099172
-
Estudio Exploratory Clinical Study of Adebrelimab Combined With Chemotherapy and Concurrent Radiotherapy Versus Sequential Radiotherapy as First-Line Treatment for Extensive-Stage Small Cell Lung Cancer（ES-SCLC）.
- Investigador principal
- Rong Yu, MD · Investigator Official Title
- Hospital
- Peking University Cancer Hospital
- Estado
- En reclutamiento
- Registro
- NCT06768307
-
Estudio A Phase 3 Randomized Open-Label Study of Adjuvant Pembrolizumab With or Without MK-2870 in Participants With Resectable Stage II to IIIB (N2) NSCLC Not Achieving pCR After Receiving Neoadjuvant Pembrolizumab With Platinum-based Doublet Chemotherapy Followed by Surgery
- Hospital
- Peking University Cancer Hospital
- Estado
- En reclutamiento
- Registro
- NCT06312137
-
Estudio Clinical Study of CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) for CEA Positive Advanced Lung Cancer
- Estado
- En reclutamiento
- Registro
- NCT06992583
-
Estudio Surgery or Radiotherapy After PD-L1 Inhibitor (TQB-2450) and Chemotherapy Induction Therapy in Patients With Limited-stage Small-cell Lung Cancer
- Investigador principal
- Peng Zhang · Director of science and education department
- Hospital
- Shanghai Pulmonary Hospital
- Estado
- En reclutamiento
- Registro
- NCT04539977
-
Estudio Exploring the Neo-Adjuvant Therapy Effects on Lung Cancer Through Monitoring and Assessment of Tumor Environment (NAT-LungMate)
- Investigador principal
- Peng Zhang · Professor
- Hospital
- Shanghai Pulmonary Hospital
- Estado
- En reclutamiento
- Registro
- NCT05857800
-
Estudio Multicenter, Retrospective, Observational Study of Icotinib for Post-Surgical Adjuvant Therapy in Stage IA2 High-Risk to IB Non-Small-Cell Lung Cancer With Positive EGFR-Sensitive Mutations
- Hospital
- Peking University Cancer Hospital
- Estado
- En reclutamiento
- Registro
- NCT07806604
-
Estudio The Shengjing Lung Cancer Cohort (SJ-LCC) Study
- Investigador principal
- Huanhuan Chen · Shengjing Hospital of China Medical University
- Hospital
- Shengjing Hospital
- Estado
- En reclutamiento
- Registro
- NCT07779005
-
Estudio A Phase II Study Evaluating Neoadjuvant Chemotherapy, Concurrent Chemoradiotherapy Combined With Dual Immune Checkpoint Blockade (PD-1/CTLA-4) in Patients With Locally Advanced Non-Small Cell Lung Cancer
- Investigador principal
- Hui Liu · Professor
- Hospital
- Sun Yat-sen University Cancer Center
- Estado
- En reclutamiento
- Registro
- NCT07103395
-
Estudio LcProt: Proteomics Longitudinal Cohort Study on Lung CancerProspective Longitudinal Cohort Study of Lung Cancer Based on Peripheral Blood and Tissue Proteomics
- Investigador principal
- Jianxing He · Professor
- Hospital
- First Affiliated Hospital of Guangzhou Medical University
- Estado
- En reclutamiento
- Registro
- NCT06778512
-
Estudio An Apen-label, Multicenter Phase II Study to Evaluate the Efficacy and Safety of BEBT-109 in Patients With EGFR Exon 20 Insertion Mutations in Locally Advanced or Metastatic Non-Small Cell Lung Cancer
- Hospital
- Guangdong Provincial People's Hospital
- Estado
- En reclutamiento
- Registro
- NCT06706713
-
Estudio Short-term Effects of Preoperative Exercise in Moderate-to-high Perioperative Risk Lung Cancer Patients(PRE-EXELUCA): a Prospective Randomized Controlled Clinical Trial
- Hospital
- Guangdong Provincial People's Hospital
- Estado
- En reclutamiento
- Registro
- NCT06215326
-
Estudio Beamion 44: A Randomized, Open-label, Multi-center Phase IIa Platform Trial to Evaluate the Safety and Tolerability of Zongertinib Plus Platinum-based Doublet Chemotherapy With or Without Pembrolizumab (and Potential Other Combinations) in Treatment-naïve Patients With Locally Advanced/Metastatic Non-squamous NSCLC With Activating HER2 Mutations
- Hospital
- Guangdong Provincial People's Hospital
- Estado
- En reclutamiento
- Registro
- NCT07486817
-
Estudio A Prospective, Multicenter, Randomized Controlled, Phase II Study of Probiotics Combined With Concurrent Hyperfractionated ChemoRadiotherapy and Adebrelimab Immunomaintenance in the Treatment of Limited-stage Small Cell Lung Cancer (LS-SCLC)
- Investigador principal
- Xingwen Fan · associate professor
- Hospital
- Fudan University Shanghai Cancer Center
- Estado
- En reclutamiento
- Registro
- NCT06943235
-
Estudio Mechanisms of Enhanced Efficacy of Ivonescimab in Neoadjuvant Therapy for Non-Small Cell Lung Cancer
- Investigador principal
- Yang Fan, MD · Vice President
- Hospital
- Peking University People's Hospital
- Estado
- En reclutamiento
- Registro
- NCT07359040
-
Estudio A Phase II/III Clinical Study on the Efficacy and Safety of TQB2450 Injection Combined With Chemotherapy or Anlotinib Hydrochloride Capsule in the Perioperative Treatment of Resectable Stage II/III Non Small Cell Lung Cancer.
- Hospital
- Cancer Hospital of Chinese Academy of Medical Sciences
- Estado
- En reclutamiento
- Registro
- NCT05913089
-
Estudio A Phase 3, Multicenter, Randomized, Open-label Study of Ifinatamab Deruxtecan (I-DXd), a B7-H3 Antibody Drug Conjugate (ADC), Versus Treatment of Physician's Choice (TPC) in Subjects With Relapsed Small Cell Lung Cancer (SCLC) (IDeate-Lung02)
- Hospital
- China-Japan Friendship Hospital
- Estado
- En reclutamiento
- Registro
- NCT06203210
-
Estudio Development and Application of a Thrombosis Risk Prediction Model in Lung Cancer Patients Treated With Immune Checkpoint Inhibitors
- Hospital
- First Affiliated Hospital of Zhengzhou University
- Estado
- En reclutamiento
- Registro
- NCT06950697
-
Estudio Exploration of and Model Establishment of the Regression Pattern of Primary Lesions in Lung Cancer After Definitive Radiotherapy
- Investigador principal
- Guangying Zhu · Clinical Professor, Chief Physician
- Hospital
- China-Japan Friendship Hospital
- Estado
- En reclutamiento
- Registro
- NCT06692972
-
Estudio A Phase 1 First-in-Human Study Evaluating Safety, Pharmacokinetics and Efficacy of ABBV 324 in Adults With Hepatocellular Cancer or Squamous Cell Non-Small Cell Lung Cancer
- Hospital
- Nanfang Hospital
- Estado
- En reclutamiento
- Registro
- NCT06858813
-
Estudio Cohort Studies of Associations of Psychological Stress With Therapy Efficacy and Prognosis of Lung Cancer, Including Non-small-cell Lung Cancer and Small-cell Lung Cancer With Early and Advanced Staging (STRESS-LUNG)
- Investigador principal
- Fang Wu · Professor
- Hospital
- Xiangya Hospital of Central South University
- Estado
- En reclutamiento
- Registro
- NCT05477979
-
Estudio Study of Propranolol Hydrochloride in Combination With Sintilimab and Platinum-based Chemotherapy for Treatment of Advanced Non-small Cell Lung Cancer (BRIO)
- Investigador principal
- Fang Wu · Chief Physician, Associate Professor
- Hospital
- Second Xiangya Hospital of Central South University
- Estado
- En reclutamiento
- Registro
- NCT05979818
-
Estudio The Associations of Sleep Disturbance With Therapy Efficacy and Prognosis of Lung Cancer, Including Non-small-cell Lung Cancer and Small-cell Lung Cancer With Early and Advanced Staging
- Investigador principal
- Fang Wu · Professor
- Hospital
- Xiangya Hospital of Central South University
- Estado
- En reclutamiento
- Registro
- NCT06975384
-
Estudio Comprehensive Multi-Omics Analysis of Early-Stage Lung Cancer Exhibiting Distinct Phenotypes
- Investigador principal
- Chen Chen · Associate Professor
- Hospital
- Second Xiangya Hospital of Central South University
- Estado
- En reclutamiento
- Registro
- NCT06699979
-
Estudio A Prospective, Single-Arm, Multicenter, Phase II Clinical Study of Chidamide Combined With Ivonescimab in the Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) With Acquired Resistance to Immunotherapy and High Yes-associated Protein (YAP) Expression
- Hospital
- Guangdong Provincial People's Hospital
- Estado
- En reclutamiento
- Registro
- NCT07412262
-
Estudio A Phase 3, Multicenter, Randomized, Open-label Trial of Trastuzumab Deruxtecan in Combination With Pembrolizumab Versus Platinum-based Chemotherapy in Combination With Pembrolizumab, as First-line Therapy in Participants With Locally Advanced Unresectable or Metastatic HER2 Overexpressing and PD-L1 TPS <50% Non-squamous Non-small Cell Lung Cancer (DESTINY-Lung06)
- Hospital
- Peking University Cancer Hospital
- Estado
- En reclutamiento
- Registro
- NCT06899126
-
Estudio Predicting Immunotherapy Response and Survival of Lung Cancer Patients Using Artificial Intelligence and Radiomics (Radiology-AI-Lung)
- Hospital
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
- Estado
- En reclutamiento
- Registro
- NCT07059923
-
Estudio Assessment the Association of Imaging and Tumor Microenvironment in Lung Cancer With Radiogenomics
- Hospital
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
- Estado
- En reclutamiento
- Registro
- NCT06500312
-
Estudio A Phase II Clinical Study to Evaluate the Efficacy and Safety of SI-B003 Monotherapy and BL-B01D1+SI-B003 Combination Therapy in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma and Other Solid Tumors
- Hospital
- Chongqing University Cancer Hospital
- Estado
- En reclutamiento
- Registro
- NCT05956587
-
Estudio The Application Value of 68Ga-grazytracer PET in Immunotherapy for Stage III Non-small-cell Lung Cancer: a Prospective, Observationa Trial
- Hospital
- Ruijin Hospital
- Estado
- En reclutamiento
- Registro
- NCT06623487
-
Estudio A Phase 3 Multicenter Open-label Study of Taletrectinib Versus a Standard of Care ROS1-Tyrosine Kinase Inhibitor (Crizotinib) in TKI-Naïve Patients With ROS1-Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer (TRUST-III)
- Hospital
- The First Affiliated Hospital of Anhui Medical University
- Estado
- En reclutamiento
- Registro
- NCT06564324
-
Estudio Impact of Intraoperative Blood Pressure Management and Dexamethasone on Patient's Outcomes After Lung Cancer Surgery: A 2 × 2 Factorial Randomized Controlled Trial
- Investigador principal
- Dong-Xin Wang · Chairman, Department of Anaesthesiology and Critical Care Medicine
- Hospital
- Peking University First Hospital
- Estado
- En reclutamiento
- Registro
- NCT04209218
-
Estudio Penpulimab-based Combination Neoadjuvant/Adjuvant Therapy for Patients With Resectable Locally Advanced Non-small Cell Lung Cancer: a Phase II Clinical Study (ALTER-L043)
- Hospital
- The First Affiliated Hospital of Nanchang University
- Estado
- Aún sin reclutar
- Registro
- NCT04846634
-
Estudio A Prospective, Multicenter Clinical Study of Hetrombopag in the Prevention of Thrombocytopenia Caused by Lung Cancer Therapy
- Investigador principal
- Ren Shengxiang · professor
- Hospital
- Jiangsu Cancer Hospital
- Estado
- Aún sin reclutar
- Registro
- NCT07101627
-
Estudio INFORM: A Prospective Interventional Study on Early Screening for Lung Cancer Using Liquid Biopsy
- Investigador principal
- Jianxing He · Professor
- Hospital
- First Affiliated Hospital of Guangzhou Medical University
- Estado
- Aún sin reclutar
- Registro
- NCT06422637
-
Estudio Selective Mediastinal Lymph Node Sampling Versus Systematic medIastinal Lymph Node Dissection After Neoadjuvant Chemotherapy Combined With Immunotherapy for the Treatment of Clinical Stage IIA-IIIB (N2) Non-small Cell Lung Cancer
- Investigador principal
- Wen-zhao ZHONG · Head of Thoracic Surgery
- Hospital
- Guangdong Provincial People's Hospital
- Estado
- Aún sin reclutar
- Registro
- NCT07617389
-
Estudio Iparomlimab and Tuvonralimab (QL1706) Combined Chemotherapy and Quad Shot Radiotherapy in First-line Treatment of Driver Gene-negative Advanced Non-small Cell Lung Cancer: a Randomized, Controlled, Phase 2, Open-label Trial.
- Hospital
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
- Estado
- Aún sin reclutar
- Registro
- NCT07271602
-
Estudio An Open, Multi-center Phase I Clinical Trial to Evaluate the Safety, Tolerability and Preliminary Efficacy of BL0020 Injection in Combination With Toripalimab Injection in Patients With Recurrent Extensive-Stage Small Cell Lung Cancer
- Hospital
- Third Affiliated Hospital of Harbin Medical University
- Estado
- Aún sin reclutar
- Registro
- NCT07550842
-
Estudio A Single-arm, Multicenter, Prospective Clinical Study of Adebrelimab Combined With Apatinib Neoadjuvant Therapy for Resectable Non-small Cell Lung Cancer
- Hospital
- First Affiliated Hospital of Xiamen University
- Estado
- Aún sin reclutar
- Registro
- NCT07031154
-
Estudio Exploratory Clinical Study on Microwave Ablation With or Without Furmonertinib for Early-Stage Non-Small Cell Lung Cancer
- Investigador principal
- Jiayuan Sun · Chief Physician
- Hospital
- Shanghai Chest Hospital
- Estado
- Aún sin reclutar
- Registro
- NCT06969781
-
Estudio Efficacy and Safety of Septum-guided Segmentectomy for 2-3 cm Clinical Stage IA3 Peripheral Non-Small Cell Lung Cancer: A Single-Center, Prospective, Single-Arm Clinical Trial
- Investigador principal
- Junfeng Geng · Professor
- Hospital
- Shanghai Chest Hospital
- Estado
- Aún sin reclutar
- Registro
- NCT07780591
-
Estudio An Open-label, Single-center, Phase II Study of Cadonilimab Monotherapy as Neoadjuvant Therapy for Resectable II-IIIA Squamous Cell Lung Cancer
- Hospital
- The First Hospital of Jilin University
- Estado
- Aún sin reclutar
- Registro
- NCT05784974
-
Estudio Postoperative Adjuvant Treatment of ALK-positive Non-small Cell Lung Cancer with Ensartinib Guided by MRD: a Single-arm, Multicenter Study
- Investigador principal
- Wu Nan · Professor
- Hospital
- Peking University Cancer Hospital
- Estado
- Aún sin reclutar
- Registro
- NCT06780839
-
Estudio Efficacy of PD-1 Inhibitor Combination Therapy in Non-small Cell Lung Cancer Patients Who Have Not Achieved Major Pathologic Response After Neoadjuvant Immunotherapy: a Multicenter, Phase II Clinical Trial
- Investigador principal
- Chang Chen · Deputy Director of MD. PhD. Program in Thoracic Surgery, Secretary of the party committee of Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, China
- Hospital
- Shanghai Pulmonary Hospital
- Estado
- Aún sin reclutar
- Registro
- NCT06620822
-
Estudio A Multicenter Randomized Controlled Trial of an Intelligent Pulmonary Function Exercise Device Versus Usual Care for In-Hospital and Home-Based Pulmonary Rehabilitation After Lung Cancer Surgery
- Investigador principal
- Jianxing He · Principal Investigator
- Hospital
- First Affiliated Hospital of Guangzhou Medical University
- Estado
- Aún sin reclutar
- Registro
- NCT07631520
-
Estudio A Randomized Controlled Trial Evaluating the Effectiveness of a Novel Risk-Stratified Screening Strategy for Lung Cancer
- Investigador principal
- Jianxing He · Principal Investigator
- Hospital
- First Affiliated Hospital of Guangzhou Medical University
- Estado
- Aún sin reclutar
- Registro
- NCT07078032
-
Estudio A Clinical Study Evaluating the Safety and Efficacy of Golidocitinib in Patients With Refractory Immune-related Hematologic Toxicities of Advanced Lung Cancer
- Investigador principal
- Jianxing He · Director, Head of Thoracic Surgery, Principal Investigator, Clinical Professor
- Hospital
- First Affiliated Hospital of Guangzhou Medical University
- Estado
- Aún sin reclutar
- Registro
- NCT07303881
-
Estudio Predictive Value of CEA and ctDNA for Postoperative Recurrence in Patients With High CEA Sensitivity Lung Cancer
- Hospital
- Guangdong Provincial People's Hospital
- Estado
- Aún sin reclutar
- Registro
- NCT07170046
-
Estudio Development of a Chest CT-Based Artificial Intelligence Model Across the Lung Cancer Care Continuum and a Prospective Randomized Crossover Reader Study of Its Clinical Decision-Support Performance
- Hospital
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
- Estado
- Aún sin reclutar
- Registro
- NCT07829640
-
Estudio A Phase II/III Clinical Study Comparing BL-B01D1 in Combination With PD-1/VEGF Bispecific Antibody Versus Chemotherapy in Combination With PD-1/VEGF Bispecific Antibody in First-line Patients With Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer(PANKU-Lung05)
- Hospital
- Sun Yat-sen University Cancer Center
- Estado
- Aún sin reclutar
- Registro
- NCT07739199
-
Estudio The Effects of Acupuncture for Lung Cancer-Related Fatigue, a Clinical Trial
- Investigador principal
- Yuanjie Sun · Doctor
- Hospital
- Guang'anmen Hospital of China Academy of Chinese Medical Sciences
- Estado
- Aún sin reclutar
- Registro
- NCT07079072
-
Estudio Neoadjuvant Sintilimab Plus Anlotinib Therapy in IB-IIIB Resectable Non-small Cell Lung Cancer (PRIORITY): a Prospective Single Center, Open Label, Phase II Study
- Hospital
- Ningbo No.2 Hospital
- Estado
- Aún sin reclutar
- Registro
- NCT06221462
-
Estudio A Randomized, Double-blind, Phase III Trial to Compare the Efficacy and Safety of AK104 Combined With Chemotherapy to Tislelizumab Combined With Chemotherapy as First-line Treatment in PD-L1 TPS < 1% Non-small Cell Lung Cancer (NSCLC)
- Hospital
- First Affiliated Hospital of Guangzhou Medical University
- Estado
- Aún sin reclutar
- Registro
- NCT05990127
-
Estudio Randomized Clinical Trials Comparing Immunotherapy Plus Cryoablation (I-CA) Versus Cryoablation Alone for Stage I, Selected Stage IIa, Non-Small Cell Lung Cancer
- Investigador principal
- Jiayuan Sun · Director, Department of Respiratory Endoscopy
- Hospital
- Tongji Hospital, Tongji Medical College, Huazhong University of Science & Technology
- Estado
- Aún sin reclutar
- Registro
- NCT06580665
-
Estudio Organoid-Based Drug Sensitivity Model Guided Personalized Precision Treatment for Extensive-Stage Small Cell Lung Cancer: A Prospective, Multicenter, Randomized Controlled Trial
- Hospital
- Peking Union Medical College Hospital
- Estado
- Aún sin reclutar
- Registro
- NCT07106528
-
Estudio A Randomized Phase 3 Multicenter Open-Label Study to Compare the Efficacy of YK-029A as First-Line Treatment Versus Platinum-Based Chemotherapy in Patients With Non-Small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations
- Hospital
- First Affiliated Hospital of Guangzhou Medical University
- Estado
- Aún sin reclutar
- Registro
- NCT05767892
-
Estudio Adebrelimab and Concurrent Radiochemotherapy as First-line Treatment for Extensive-stage Small-cell Lung Cancer
- Hospital
- Henan Cancer Hospital
- Estado
- Aún sin reclutar
- Registro
- NCT06236997
-
Estudio An Investigator-initiated Trial Evaluating the Efficacy and Safety of Anti-Trop2 Universal CAR-NK(U-CAR-NK) Cells Therapy Combined With Chemotherapy for Relapsed/Refractory Non-Small Cell Lung Cancer (NSCLC)
- Investigador principal
- Qiming Wang · Professor
- Hospital
- Henan Cancer Hospital
- Estado
- Aún sin reclutar
- Registro
- NCT06454890
-
Estudio Adebrelimab Combined With Oral Etoposide for Elderly Patients and Patients With Poor Performance Status in Small Cell Lung Cancer: An Exploratory Clinical Study
- Investigador principal
- Liu Fang · Director
- Hospital
- Third Affiliated Hospital of Harbin Medical University
- Estado
- Aún sin reclutar
- Registro
- NCT07398560
-
Estudio Stereotactic Body Radiotherapy With Sequential Iparomlimab and Tuvonralimab (QL1706) + Chemotherapy as Neoadjuvant Therapy in Patients With Resectable Non-small-cell Lung Cancer in China (LUNG-Nanjing01): a Single-arm, Single-centre, Phase 2 Trial
- Investigador principal
- Zhang Zhi · Associate Professor
- Hospital
- Jiangsu Cancer Hospital
- Estado
- Aún sin reclutar
- Registro
- NCT07286942
-
Estudio Efficacy and Safety of Induction Chemoimmunotherapy Followed by Carbon Ion Radiotherapy and Consolidation Immunotherapy in Unresectable Locally Advanced Non-small Cell Lung Cancer
- Investigador principal
- Ji Yongling · PI
- Hospital
- Zhejiang Cancer Hospital
- Estado
- Aún sin reclutar
- Registro
- NCT07035860
-
Estudio A Prospective, Multicenter, Randomized Controlled Clinical Trial Comparing Bronchoscopic Thermal Vapor Ablation and Percutaneous Microwave Ablation in Patients With COPD and Early-Stage Lung Cancer: Efficacy and Safety Evaluation
- Hospital
- Henan Provincial People's Hospital
- Estado
- Aún sin reclutar
- Registro
- NCT06929390
-
Estudio Effects of Different Preoperative Oral Rehydration Protocols on Safety, Comfort, and Postoperative Outcomes in Elderly Patients Undergoing Thoracoscopic Radical Lung Cancer Surgery: A Randomized Controlled Trial
- Hospital
- Fujian Medical University Union Hospital
- Estado
- Aún sin reclutar
- Registro
- NCT07042503
-
Estudio The Impact of SGLT2i on the Outcome of Advanced Lung Cancer in Patients With Diabetes
- Investigador principal
- Liang Zhao · Dr
- Hospital
- Shanghai Chest Hospital
- Estado
- Aún sin reclutar
- Registro
- NCT07272057
-
Estudio Phase I Study of Anti-EGFR/c-Met Bispecific Antibody MCLA-129 Combined With Befotertinib in Patients of Advanced Non-small Cell Lung Cancer With EGFR Sensitive Mutation To Evaluate The Safety, Pharmacokinetic Characteristics and Antitumor Activity
- Hospital
- First Affiliated Hospital of Guangzhou Medical University
- Estado
- Aún sin reclutar
- Registro
- NCT06015568
-
Estudio A Single-Arm Phase II Study of Intrathecal Thiotepa Via Ommaya Reservoir for Leptomeningeal Metastases in Non-Small Cell Lung Cancer Resistant to EGFR-TKI
- Hospital
- Tianjin Medical University Cancer Institute & Hospital
- Estado
- Aún sin reclutar
- Registro
- NCT07778940
-
Estudio A Prospective, Multicenter Exploratory Clinical Study on Consolidation Therapy With Tislelizumab Combined With Nintedanib for Limited-stage Small Cell Lung Cancer
- Hospital
- The Affiliated Hospital of Qingdao University
- Estado
- Aún sin reclutar
- Registro
- NCT07485920
-
Estudio A Multicenter Exploratory Clinical Study of Iruplaltinib Combined With Pemetrexed as Neoadjuvant Therapy for Resectable ALK-Positive Non-Squamous Non-Small Cell Lung Cancer
- Hospital
- The First Affiliated Hospital of Fujian Medical University
- Estado
- Aún sin reclutar
- Registro
- NCT07771764
-
Estudio Comparing the Efficiency Between Surgery and Radiotherapy After SHR-1316 (Adebrelimab) and Platinum-containing Doublet Induction Therapy for Limited-stage Small Cell Lung Cancer: a Randomized, Controlled, Open-label, Single-center Phase III Clinical Trial
- Investigador principal
- Peng Zhang · associate professor of medicine
- Hospital
- Shanghai Pulmonary Hospital
- Estado
- Aún sin reclutar
- Registro
- NCT05496166
-
Estudio Furmonertinib Combined With Local Therapy in Inoperable or Surgery-Refusing Early-Stage Non-Small Cell Lung Cancer:A Single-arm, Phase II Study
- Investigador principal
- Xuefei Hu · Chief Physician
- Hospital
- Shanghai Pulmonary Hospital
- Estado
- Aún sin reclutar
- Registro
- NCT07517640
-
Estudio A Phase II Clinical Study of Adebelizumab Combined With Other Anti-tumor Treatments as a Perioperative Treatment for Resectable Non-small Cell Lung Cancer
- Hospital
- Shanghai Pulmonary Hospital
- Estado
- Aún sin reclutar
- Registro
- NCT07704645
-
Estudio An Observational Study on the Impact of the 23-valent Pneumonia Vaccine on the Incidence of Pulmonary Infection and Survival in Lung Cancer Patients
- Investigador principal
- Yalei Zhang · The First Affiliated Hospital of Guangzhou Medical University
- Hospital
- First Affiliated Hospital of Guangzhou Medical University
- Estado
- Aún sin reclutar
- Registro
- NCT07142057
-
Estudio Explore the Mechanisms Underlying Disease Resistance and Potential Primary Resistance Mechanism of Induction Therapy Lorlatinib in Resectable Non-small Cell Lung Cancer (NSCLC) Harboring ALK Positive Mutation Revealed by Single-cell RNA Sequencing and Spatial Transcriptomics
- Investigador principal
- Jianxing He · Chief physician
- Hospital
- First Affiliated Hospital of Guangzhou Medical University
- Estado
- Aún sin reclutar
- Registro
- NCT06893354
-
Estudio Phase II, Open-label, Single-arm, Prospective, Multi-center Study to Evaluate the Efficacy and Safety of Lorlatinib as Neoadjuvant Treatment in Surgically Resectable Stage IB-IIIB ALK-rearranged Non-Small Cell Lung Cancer (NEOLORA)
- Investigador principal
- Yang Fan, MD · Professor of Thoracic Surgery
- Hospital
- Peking University People's Hospital
- Estado
- Aún sin reclutar
- Registro
- NCT06682884
-
Estudio The Diagnostic Value of Bronchoscopic Needle-based Confocal Laser Endomicroscopy (nCLE) As a Real-time Detection Tool for Diagnosing Peripheral Lung Cancer: a Multi-centre Randomised Controlled Trial
- Investigador principal
- Gang Hou · Professor
- Hospital
- China-Japan Friendship Hospital
- Estado
- Aún sin reclutar
- Registro
- NCT06739421
-
Estudio A Multi-cohort, Open-label Phase II Study to Evaluate the Efficacy and Safety of the Anti-EGFR/c-Met Bispecific Antibody MCLA-129 in Patients with Advanced Non-Small Cell Lung Cancer with Actionable Gene Alterations and MET Amplification.
- Hospital
- The First Affiliated Hospital of Anhui Medical University
- Estado
- Aún sin reclutar
- Registro
- NCT06885840
Esta página solo comparte información de estudios registrados públicamente. No recomienda ni anima a participar en ningún estudio. La participación es totalmente voluntaria y los riesgos de un tratamiento no aprobado son desconocidos; contacta directamente con el hospital para conocer los criterios de elegibilidad y los detalles del consentimiento informado.
Terapias avanzadas: qué está autorizado y qué está en ensayos
Hospitales con un registro de especialidad clave nacional
Mostrar los registros de hospitales 46 hospitales con un registro de especialidad clave
Cada fila es un hospital con un registro de especialidad clínica clave nacional en una especialidad en la que se clasifica esta enfermedad. Es un registro de listados publicados, no una recomendación ni un ranking.
46 hospitales con un registro de especialidad clave nacional que coincide.
Los valores escritos en chino se citan tal como los publica la fuente.
Lo que reportan los pacientes
Solo cifras agregadas: un resultado nacional citado con su fuente y el año al que se refiere. No es el testimonio de un paciente ni una afirmación sobre una sola persona.
Según lo publicado en National Health Commission - 2023 national tertiary public hospital performance monitoring circular (国卫医政函〔2025〕55 号) (2023): National inpatient satisfaction / outpatient satisfaction — 95.42 / 93.95 score, 0-100.
National aggregate across the 2,168 tertiary public hospitals that took part in the national performance monitoring (all conditions combined; not disease-specific, not hospital-specific).
Fuente: National Health Commission - 2023 national tertiary public hospital performance monitoring circular (国卫医政函〔2025〕55 号) — https://www.gov.cn/zhengce/zhengceku/202503/content_7016208.htm — 2023 — Nivel A
Efectos secundarios reportados
La tasa de un efecto secundario en un solo ensayo clínico, citada con su fuente y la fecha en que se obtuvo. Es una tasa de un solo ensayo, no una tasa nacional.
Según lo publicado en ClinicalTrials.gov results - NCT01310036 (2026-10-05): Pneumonia (serious adverse event) — 10 / 207 (about 4.8%) participants.
Single trial: erlotinib 150 mg daily, safety population n=207, systematic assessment, MedDRA 19.1, 5% frequency threshold. It is a single-trial rate for one study population, not a national rate.
Fuente: ClinicalTrials.gov results - NCT01310036 — https://clinicaltrials.gov/api/v2/studies/NCT01310036 — 2026-10-05 — Nivel B
Todos los temas de terapias y acceso
Preguntas sobre esta enfermedad
No podemos dar asesoramiento médico, pero sí responder preguntas sobre esta página y sobre cómo organizar un tratamiento en China.
Códigos CIE
Mostrar la tabla de códigos 7 códigos CIE
| Versión | Código | Nombre en esa versión |
|---|---|---|
| ICD-10-WHO | C34 | Malignant neoplasm of bronchus and lung |
| ICD-10-WHO | C34.0 | Main bronchus |
| ICD-10-WHO | C34.1 | Upper lobe, bronchus or lung |
| ICD-10-WHO | C34.2 | Middle lobe, bronchus or lung |
| ICD-10-WHO | C34.3 | Lower lobe, bronchus or lung |
| ICD-10-WHO | C34.8 | Overlapping lesion of bronchus and lung |
| ICD-10-WHO | C34.9 | Bronchus or lung, unspecified |
Las filas son las entradas CIE-10 de la OMS para esta enfermedad, citadas tal como se publicaron.
Fuente y evidencia
- URL de la fuente
- https://wjw.fujian.gov.cn/xxgk/fgwj/zxwj/201904/P020190412506737868905.xlsx
- Esquema de la fuente
- https
- Tipo de fuente
- Comisión de salud provincial
- Nivel de evidencia
- A - declarado por una comisión de salud, un instituto nacional de investigación o una universidad
- Recuperado el
- 2026-09-24